Thrombolex
Kingston, US · Founded 2016 · Delaware corporation · 1 known investors
Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots. Its FDA-cleared products are based on the BASHIR Endovascular Catheter platform for medical practitioners treating vascular disease.
Founders & leadership
Thrombolex was founded in 2016 by Riyaz Bashir.
RB
Riyaz BashirInnovator / Creator of BASHIR Endovascular Catheters
JC
John CerminaroExecutive
MJ
Michael J. CerminaroExecutive
MW
Marvin WoodallNamed on SEC filing
BG
Brian G. FirthNamed on SEC filing
TR
Todd RichmondNamed on SEC filing
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$55.6M disclosed across 6 rounds · 2017–2026
▶$32.8MraisedMar 2026 · 22 investors · Other Health CareRule 506(b)
▶$32.8MraisedMar 2026 · 22 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David BonitaDirector
- Keegan HarperDirector
- Paul A. StewartDirector
- Sam LiangDirector
- Marvin WoodallExecutive Officer, Director
- John CerminaroExecutive Officer
- Clay DeMarcusDirector
- Michael J. CerminaroExecutive Officer, Director
- Offering amount
- $51.1M
- Amount sold
- $32.8M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedJun 2024 · 5 investors · Other Health CareRule 506(b)
▶$1.2MraisedJun 2024 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John CerminaroExecutive Officer
- Marvin WoodallDirector
- Kelly ElliottDirector
- Todd RichmondDirector
- Michael J. CerminaroExecutive Officer, Director
- Tony LitwillerExecutive Officer
- Paul A. StewartDirector
- Offering amount
- $5M
- Amount sold
- $1.2M
- Minimum investment
- $50K
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.8MraisedMay 2024 · 56 investors · Other Health CareRule 506(b)
▶$4.8MraisedMay 2024 · 56 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Tony LitwillerExecutive Officer
- Paul A. StewartDirector
- Marvin WoodallDirector
- Kelly ElliottDirector
- John CerminaroExecutive Officer
- Michael J. CerminaroExecutive Officer, Director
- Todd RichmondDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedAug 2022 · 50 investors · Other Health CareRule 506(b)
▶$2MraisedAug 2022 · 50 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Marvin WoodallExecutive Officer, Director
- Paul A. StewartDirector
- Michael J. CerminaroExecutive Officer, Director
- John CerminaroExecutive Officer
- Todd RichmondDirector
- Brian G. FirthExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedNov 2021 · 46 investors · Other Health CareRule 506(b)
▶$5MraisedNov 2021 · 46 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. StewartDirector
- Michael J. CerminaroExecutive Officer, Director
- Brian G. FirthExecutive Officer, Director
- Todd RichmondDirector
- John CerminaroExecutive Officer
- Marvin WoodallExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$9.8MraisedFeb 2020 · 33 investors · Other Health CareRule 506(b)
▶$9.8MraisedFeb 2020 · 33 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Marvin WoodallExecutive Officer, Director, Promoter
- Michael J. CerminaroExecutive Officer, Director, Promoter
- Brian G. FirthExecutive Officer, Director
- Paul A. StewartDirector
- Todd RichmondDirector
- John CerminaroExecutive Officer
- Amount sold
- $9.8M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBoston Scientific8 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Doximity6 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Read the Press Release5 shared keywordsStryker is a medical technology company that develops and manufactures products across areas such as orthopaedics, surgical equipment, neurotechnology, and spine care for hospitals and healthcare providers. It operates globally across the Americas, Europe, Asia-Pacific, and the Middle East.
Inari Medical5 shared keywordsInari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis. Its product portfolio includes the FlowTriever and ClotTriever systems, catheters, and blood return systems used by clinicians treating vascular blood clots.
Companies competing with Thrombolex for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Thrombolex do?
- Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots. Its FDA-cleared products are based on the BASHIR Endovascular Catheter platform for medical practitioners treating vascular disease.
- Who founded Thrombolex?
- Thrombolex was founded by Riyaz Bashir in 2016.
- Who are Thrombolex's investors?
- Thrombolex's investors include OrbiMed.
- How much funding has Thrombolex raised?
- Thrombolex has disclosed $55.6M raised across 6 rounds.
- Where is Thrombolex headquartered?
- Thrombolex is headquartered in Kingston, US.